linjc16/ctgov huggingface dataset:
Timolol Eye Drops in the Treatment of Acute Migraine Headache

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.

Official Title
-----------------
Timolol Eye Drops in the Treatment of Acute Migraine Headache

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Timolol eye drops
* Drug: Artificial tears


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of migraine headache Exclusion Criteria Non-migraine headache Use of systemic beta-blocker Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications Previous adverse reaction to timolol or other beta-blockers Inability to self-administer eye drop due to physical or cognitive disorders Currently pregnant or breastfeeding Pregnant in the past year Non-english speaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Timolol eye drops<br>All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study. | Drug: Timolol eye drops<br>* eye drops<br>|
| Placebo Comparator: Artificial tears<br>All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study. | Drug: Artificial tears<br>* Placebo drop<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Timolol Eye Drops in the Treatment of Acute Migraine Headache | Percent of migraine attacks at 0 or 1 on the 4-point Rating Scale recommended by the International Headache Society: 0: no headache mild headache moderate headaches severe headache | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
headache
The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding

Study Overview
=================
Brief Summary
-----------------
Determine the effect of high-dose pancreatic enzyme supplementation on nutritional indicators and clinical course in critically ill patients undergoing enteral nutrition.

Official Title
-----------------
The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding: Prospective Randomized Controlled Trial

Conditions
-----------------
Critically Ill, Enteral Feeding, Exocrine Pancreatic Insufficiency

Intervention / Treatment
-----------------
* Drug: Exocrine Pancreatic Enzyme
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults 19 years and older Hospitalized in the surgical/medical intensive care unit of the Seoul National University Hospital Enteral nutrition Patients who consented to this study Patients with risk factors for pancreatic exocrine dysfunction Shock (Norepinephrine) Sepsis (3 rd definition of sepsis) Diabetes Cardiac arrest hyperlactatemia serum lactate > 2 mmol/L) Mechanical ventilation Continuous renal replacement therapy Exclusion Criteria: chronic pancreatitis unresectable pancreatic cancer History of pancreatectomy Underlying diseases in which the effect of Exocrine pancreatic enzyme administration is difficult to show Inflammatory bowel disease Short bowel syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Exocrine Pacancreatic enzyme(Norzyme Capsule 40000 capsules) after meals 3 times a day | Drug: Exocrine Pancreatic Enzyme<br>* Pancreatic enzyme supplementation for critically ill patients on enteral nutrition<br>* Other names: Norzyme;|
| Placebo Comparator: Control<br>Placebo after meals 3 times a day | Drug: Placebo<br>* Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Phase angle (°) | Change from Baseline Phase angle (°) at 2 weeks or discharge | Baseline, 7 days after starting enteral nutrition, 14 days after starting enteral nutrition | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skeletal Muscle Mass (SMM) (kg) | Skeletal Muscle Mass (SMM) (kg) | Baseline, 7 days after starting enteral nutrition, 14 days after starting enteral nutrition |
Treatment of Hypertension With Adalat® in Combination With Other Drugs

Study Overview
=================
Brief Summary
-----------------
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Official Title
-----------------
AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Nifedipine (Adalat, BAYA1040)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously untreated hypertensive patients starting with combination therapy containing nifedipine or Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy Exclusion Criteria: None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Nifedipine (Adalat, BAYA1040)<br>* Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients |  | After three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Drug therapy, combination
Follicular Fluid Raman Shifts and IVF Outcomes

Study Overview
=================
Brief Summary
-----------------
This study intends to collect about 150 cases of follicular fluid samples from PCOS and non-PCOS infertility patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles (in clinical routines).We tend to detect Raman metabolic profile of the follicular fluid of the PCOS and non-PCOS groups, and find the correlation between the metabolic profile of the follicular fluid of PCOS patients and the oocyte quality, IVF outcome and subsequent embryo development are also under investigation. Metabolomics analysis was applied to look for markers of follicular fluid in PCOS patients, and further exploring data and strategies to improve the embryonic development potential and IVF outcome of PCOS patients.

Official Title
-----------------
The Correlation Between Follicular Fluid Raman Spectrum and Embryo Development in Infertile Patients With Polycystic Ovary Syndrome

Conditions
-----------------
IVF, Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Raman spectrum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients fit the Rotterdam criteria for PCOS Patients under IVF cycles Exclusion Criteria: Patients with male factors infertility Patients with fallopian tube factors infertility
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PCOS follicular fluid<br> | Diagnostic Test: Raman spectrum<br>* The wavelength of the follicular fluids were scaned by Raman spectrum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between polycystic ovary syndrome and normal follicular fluids | Raman spectrum was applied and the Raman spectrum characteristic absorption peak can be revealed. PCA analysis was used to measure the degree of differential shifts. | 24 months |
Acute Effects of Aerobic Exercise on Motor Memory Consolidation in Older People

Study Overview
=================
Brief Summary
-----------------
Scientific evidence suggests that an aerobic exercise session promotes improvements in the consolidation of motor memory in adults. In this sense, the main purpose of this study was to investigate if an aerobic training session could improve motor memory consolidation in older people.

Detailed Description
-----------------
The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.

Official Title
-----------------
Acute Effects of Aerobic Exercise on Motor Memory Consolidation in Older People

Conditions
-----------------
Elderly

Intervention / Treatment
-----------------
* Other: Aerobic exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: sensory abnormalities; mental abnormalities; motor abnormalities; other atypical health problems.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training. | Other: Aerobic exercises<br>* The training session lasted 45 minutes and was composed of running exercises.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The participants performed a Soda Pop test before the aerobic training session (Baseline). | The participants performed a Soda Pop test before the aerobic training session (Baseline). | The participants performed a Soda Pop test before the aerobic training session (Baseline). |
Abdominal Aortic Aneurysm Screening Before Coronary Artery Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
Coronary artery disease (CAD) and abdominal aortic aneurysm (AAA) are two separate entities with common risk factors such as hypertension, advanced age, male sex. Atherosclerosis plays an important role in the etiology of both diseases. It has been reported that AAA is more prevalent in patients undergoing coronary artery bypass grafting (CABG). Despite all the evidence, current guidelines do not recommend routine screening for AAA before CABG. Syntax score shows anatomical significance of CAD and is associated with the degree of atherosclerotic load. The investigators aim to investigate if there were any differences regarding AAA prevalence in high-SYNTAX patients versus intermediate/low-SYNTAX patients.

Official Title
-----------------
Association of SYNTAX Score With Abdominal Aortic Aneurysm in Patients Undergoing Coronary Artery Bypass Graft Surgery: Who Should be Screened?

Conditions
-----------------
Abdominal Aortic Aneurysm, Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Abdominal aortic Duplex ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing coronary artery bypass graft surgery Age >18 years Exclusion Criteria: Age <18 years Pregnancy Breastfeeding Emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High-SYNTAX score patients<br> | Diagnostic Test: Abdominal aortic Duplex ultrasound<br>* All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.<br>|
| Intermediate/low-SYNTAX score patients<br> | Diagnostic Test: Abdominal aortic Duplex ultrasound<br>* All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infrarenal abdominal aortic diameter | Infrarenal abdominal aortic diameter measured by bedside Duplex ultrasound by the principal investigator, Dr. Ozeren-Topcu | Baseline |
Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of escalating multiple doses of ORM-12741 in healthy volunteers

Official Title
-----------------
Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: ORM-12741


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good general health ascertained by detailed medical history and physical examinations Males between 18 and 45 years Body mass index (BMI) between 18-30 kg/m2 Weight 55-90 kg Exclusion Criteria: Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease Any condition requiring regular concomitant treatment including herbal products or likely to need any concomitant treatment during the study Susceptibility to severe allergic reactions Regular consumption of more than 14 units of alcohol per week Current use of nicotine-containing products more than 5 cigarettes or equivalent/day Inability to refrain from using nicotine-containing products during the stay in the study centre Inability to refrain from consuming caffeine-containing beverages during the stay in the study centre Blood donation or loss of significant amount of blood within 3 months prior to the screening visit Abnormal finding in ECG, vital signs, laboratory tests or physical examination Participation in a drug study within 3 months prior to the start of this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ORM-12741<br> | Drug: ORM-12741<br>* Alternating panel multiple dose escalation<br>|
| Placebo Comparator: Placebo<br> | Drug: ORM-12741<br>* Alternating panel multiple dose escalation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values |  | about a month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics |  | 12 days per period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy volunteer study
Descriptive Analysis: STarT Back Screening Tool: Cross-sectional Survey & Chart Review

Study Overview
=================
Brief Summary
-----------------
Keele STarT Back SCreening Tool (KSB) is a practical and validated bio-psychosocial questionnaire that stratifies lower back pain patients into 3 risk groups (low, medium, high), with suggested treatment guidelines for each grouping. The 9-question KSB has been used in chiropractic practice to help guide medical decision making, but its use in chiropractic teaching environments has been limited.

Detailed Description
-----------------
All new LBP patients between the ages of 18-65 years presenting to a chiropractic teaching clinic in Dallas, TX between March 05, 2018 and April 06, 2018 were asked to complete the KSB questionnaire. No introduction of the KSB was given to students or faculty. For all patients that completed the KSB, a chart review of the first 4 weeks of care was completed to retrieve patient follow-up information and treatment provided, including: self-reported LBP on a 10-point numerical rating scale (NRS), region of spinal manipulation therapy (SMT), and active rehabilitation provided.

Official Title
-----------------
A Descriptive Analysis of Back Pain Patient's Seeking Care at Chiropractic Academic Teaching Clinics Using the STarT Back Screening Tool: Cross-sectional Survey and Chart Review

Conditions
-----------------
Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the age of 18-65 years old. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chiropractic care Questionnaire | Nine question Keele STarT Back questionnaire to identify treatment options for individuals with low, moderate, and high risk low back pain. A 10 point numerical rating scale (NRS) was used to with 0-4 being low risk, 5 being moderate risk, and 6-10 being high risk. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Low back pain self reported | Oswestry low back pain scale/ tool: 10 point scale with 0 being no pain and 10 being excruciating pain. | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chiropractic, Screening tool, Teaching